Business Wire

CO-ADTRAN

30.4.2024 14:01:32 CEST | Business Wire | Press release

Share
Commnet Broadband transforms in-home connectivity across rural American Southwest with Adtran Intellifi®

Adtran today announced that Commnet Broadband is leveraging Intellifi® as part of its Mosaic One software-as-a-service (SaaS) solution to enhance in-home connectivity as the service provider scales across the American Southwest. The cloud-managed Wi-Fi solution will enable Commnet Broadband to deliver a seamless, always-on mesh Wi-Fi experience, boosting subscriber satisfaction while driving new efficiencies. With a strong commitment to digital inclusion, Commnet Broadband is extending its reach into more underserved rural communities, connecting them with reliable and high-quality internet services. Deploying Mosaic One for remote service activation and troubleshooting, along with Intellifi® for AI-driven insights and complete control over the home Wi-Fi environment, enables the company to efficiently manage its expansive and diverse network infrastructure.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430732731/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Adtran’s Mosaic One and Intellifi® are helping Commnet deliver robust Wi-Fi services to underserved communities. (Photo: Business Wire)

“At Commnet Broadband, our mission is to empower underserved regions of America through reliable and personalized internet access. With Adtran’s Intellifi® solution, we’re taking our service delivery capabilities to the next level, ensuring uninterrupted and hassle-free Wi-Fi for both fiber and fixed wireless customers across our footprint,” said Scott Horne, CEO of Commnet Broadband. “One key advantage of our new system is the enhanced visibility it offers into customer premises, reducing the need for tier 1 tech support and minimizing truck rolls. Features like network-wide speed tests will enable us to analyze detailed heat maps, revealing our network’s strengths and pinpointing areas for improvement. This clear understanding of latency and speed capabilities will help us uplift the most isolated communities, ensuring we make a real and impactful difference.”

Adtran’s Intellifi®, part of the Mosaic One suite, provides a robust, cloud-hosted portal that transforms home Wi-Fi management for Commnet Broadband’s subscribers. It enhances customer support with features like Intellifi® MeshView, an operator portal that facilitates automated issue detection and remote resolution. The Intellifi® mobile app supports subscriber self-installs and offers comprehensive network control, including parental settings and device management. Mosaic One equips network engineers with predictive tools that monitor network access and identify at-risk connections. This proactive approach not only helps preemptively address issues, thereby reducing the need for on-site repairs, but it also enhances network reliability and subscriber uptime. Adtran’s Wi-Fi 6 service delivery gateways (SDGs) and mesh satellites also help ensure an exceptional Wi-Fi experience for subscribers.

“We’re excited to support Commnet Broadband as they expand their reach into more digitally excluded areas and elevate their services for all subscribers. With our Mosaic One and Intellifi® solutions, they can harness the full potential of managed Wi-Fi. That means delivering true Gigabit and multigigabit speeds and a superior level of service,” commented John Scherzinger, GM of Americas sales at Adtran. “The comprehensive telemetry, insights and user experience data that Intellifi® provides will empower Commnet Broadband to tailor services more precisely to each customer’s needs. Our virtual field technician feature can also cut operational costs, generating substantial savings per truck roll. Moreover, our technology creates new revenue opportunities, enabling Commnet Broadband to offer differentiated services that cater to the specific needs of communities, businesses and families.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

About Commnet Broadband

Commnet Broadband, wholly owned subsidiary of ATN International, Inc. (NASDAQ: ATNI), provides high-quality broadband communications services to carrier customers in rural America and Tribal communities, driving digital inclusion and providing access to education, work, healthcare, safety, entertainment, and community connectivity. Learn more at www.commnetbroadband.com.

Published by

ADTRAN Holdings, Inc.

www.adtran.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240430732731/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release

If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release

This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release

New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye